Can weight loss injections kill you? A clear-eyed look at the real risks

What does the trial and regulatory evidence actually show?

No medicine is risk-free, and GLP-1 receptor agonists are no exception. In the large-scale SURMOUNT-1 trial, which enrolled thousands of adults, serious adverse events did occur, but their rate was comparable to placebo, and no treatment-related deaths were confirmed in that programme. Tirzepatide and semaglutide (the active ingredients in Mounjaro and Wegovy) have since been reviewed by the MHRA, the NICE committee, and regulators across dozens of countries. Both hold UK marketing authorisations and Black Triangle (▼) status, meaning MHRA monitoring of their safety profile continues actively after approval.

The most clinically important risk is acute pancreatitis. On 29 January 2026 the MHRA published a Drug Safety Update specifically for GLP-1 medicines, confirming that acute pancreatitis is an infrequent but potentially serious side effect. The warning sign is severe, persistent stomach pain that spreads toward the back, with or without vomiting. If that happens, stop using the injection and go to A&E or call 999, do not wait to see whether it passes. Gallbladder problems are also more common than in the general population on these medicines. Neither makes the medicine categorically dangerous for the right patient; both make prescriber assessment essential.

Gastrointestinal effects are far more common but rarely dangerous in healthy adults. Nausea, vomiting and diarrhoea can cause dehydration, and for people with kidney problems that dehydration can become serious quickly. Again, this is exactly the sort of thing a prescriber needs to know about before treatment starts, which is why it appears on the medical-history questionnaire, not as a footnote.

When does the risk profile become genuinely alarming?

The risk calculation shifts sharply when people access these injections outside a legitimate clinical pathway. This is not a theoretical concern. The MHRA has seized approximately 20 million doses of illegally traded weight loss medicines with a street value of around £45 million, and in October 2025 raided the first illicit UK manufacturing site producing counterfeit tirzepatide pens. Some fake pens previously seized by the MHRA contained insulin. An accidental injection of insulin in someone without diabetes can cause life-threatening hypoglycaemia within minutes, that is where the question of lethality becomes very real.

Sellers operating on social media or websites that offer these medicines without a prescription are a serious red flag. Legitimate supply chains are regulated; unregulated ones are not, and there is no reliable way to tell from a pen's appearance whether it contains what the label claims. The MHRA advises verifying any online pharmacy on the GPhC register before placing an order. If a seller is not listed there, walk away. You can report suspected illegal sellers directly through the MHRA Yellow Card scheme.

Even with a genuine pen, using the wrong dose, injecting in the wrong site, or continuing treatment through contraindicated conditions can amplify risk. Every dose increase benefits from a clinical re-check, not just a repeat order.

Who should not use weight loss injections at all?

There are groups for whom these medicines are not appropriate, regardless of weight or motivation. They are not licensed for anyone under 18. They are not recommended during pregnancy, while breastfeeding, or when actively trying to conceive, and the MHRA advises using effective contraception throughout treatment with a wash-out period before trying for a baby.

A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 rules out tirzepatide. A history of pancreatitis requires careful prescriber assessment. Certain gastrointestinal conditions, severe kidney or liver impairment, and a range of drug interactions also need to be weighed carefully, this is precisely what an overview of weight loss injections cannot substitute for a proper consultation.

If you are curious about how long you can use weight loss injections and what stopping looks like, the practical detail is covered on a separate page about treatment duration. Understanding the full picture before starting is the safest place to begin. You might also find it helpful to read about how long you can take weight loss injections, a question our clinical team addresses alongside the guide on stopping weight loss injections.

How does a regulated pharmacy reduce these risks in practice?

If you are reading this because you are nervous (or because someone in your life has raised concerns) that reaction is understandable and worth taking seriously. The fact that you are asking the question before starting treatment puts you in a better position than many people who order first and research later.

At nume, every consultation is read by a named, GPhC-registered Independent Prescriber the same day. Not a chatbot, not an automated decision tree, a real clinician, reading your answers and checking them against your medical history. ID and live weight verification are part of every new assessment. If something in your history makes these medicines unsuitable, we will tell you plainly and explain why. Medicines are dispensed only through our own GPhC-registered pharmacy (registration number 9012878, verifiable at the GPhC register), and every repeat order gets a clinical re-review before dispatch.

Questions about cost and what is included in the price are answered on our weight loss injection pricing page. The short version: one price covers the consultation, prescription, medicine and free next-working-day delivery, with aftercare available seven days a week if a side effect worries you.

If you would like a prescriber to assess your suitability, check your eligibility with a free consultation.